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were conducted in South America (92%), particularly in Brazil (64%). The mean age 
was 60 ± 9 years and the mean ejection fraction was 36 ± 9%. Most studies evalu-
ated more than one etiology (79%) but the etiology more studies exclusively was 
Chagas disease (13%). The incidence of HF ranged from 199 to 557 cases per 100,000 
person-years and the pooled prevalence was 1%, being higher in older populations. 
Hospitalization rates in patients with HF ranged from 28 to 31% at different time 
points, and the median length of stay was 7.0 days. In-hospital mortality was 11.7%, 
being higher in patients with worse ejection fraction, with ischemic and with Chagas 
disease. Mortality at one year was 24.52% (95%CI 19.42 to 30.02). ConClusions: 
This SR of HF in Latin America, could help decision-makers to design better preven-
tive strategies, and guide effective patient-centered care.
CARDIOVASCULAR DISORDERS – Cost Studies
PCV7
BUDgEt ImPACt AnALySIS Of thE USE Of ALtEPLASE In thE tREAtmEnt Of 
ACUtE ISChAEmIC StROkE In mExICO
Huicochea-Bartelt JL1, Palacios E2, Zapata L2, Herran S1
1Boehringer Ingelheim, Distrito Federal, Mexico, 2Guia Mark, Distrito Federal, Mexico
objeCtives: To estimate the economic impact of the use of alteplase versus best 
supportive care (BSC) in patients with acute ischemic stroke in Mexico. Methods: 
A decision tree cost-effectiveness (CE) model assessed the treatment related cost for 
Alteplase and BSC related to two mayor disease branches: with or without intrac-
ranial hemorrhage. Terminal nodes in each arm included death, independent- or 
dependent survival. Published results of head to head clinical trials efficacy inputs 
populated the model. Treatment algorithm was obtained from the local governmen-
tal guide. Public institutional direct medical costs (2014 purchases and price tabula-
tors) where retrieved to adopt the national health system perspective. Governmental 
databases and 2014 purchases provided the epidemiology inputs. A five year fore-
cast estimated the budget impact of the use of alteplase versus BSC. Results: 
7,976 patients yearly were calculated to require medical attention due to an acute 
ischaemic stroke in Mexico. Mean saving per patient in the alteplase versus BSC 
arm was estimated to be US$67,142.76 at the CE model. 16% versus 12% positive 
response to treatment was seen at alteplase and BSC arms respectively. Starting 
at a 4% Market share level, and assuming an increasing share at a 1% rate per year, 
potential savings for new cases at year five (8% share) were estimated to be as high 
as US$35,342,527.00. ConClusions: At a better response rate with lower costs of 
treatment, alteplase was estimated to be a cost-saving therapy versus BSC in a CE 
model. In a five year budget impact analysis, this novel alternative showed to bring 
potential savings in the public Mexican institutional context versus BSC. The savings 
proportionally increase with a higher levels of patients treated and market share.
PCV8
BUDgEt ImPACt AnALySIS Of thE USE Of tEnECtEPLASE In thE tREAtmEnt 
Of ACUtE myOCARDIAL InfARCtIOn In mExICO
Huicochea-Bartelt JL1, Palacios E2, Zapata L2, Herran S1
1Boehringer Ingelheim, Distrito Federal, Mexico, 2Guia Mark, Distrito Federal, Mexico
objeCtives: To estimate the economic impact of the use of tenecteplase versus 
streptokinase in patients with acute myocardial infarction (AMI). Methods: A 
decision tree cost-effectiveness (CE) model assessed the treatment related cost 
for tenecteplase and streptokinase related to two mayor disease branches: with or 
without acute reperfusion therapy. In the reperfusion arm, terminal nodes included 
none or one or more complications; those without therapy could only survive or 
die. Complications comprised death, reinfarction, cardiac failure, cerebral infarc-
tion, minor and mayor bleedings and intracranial hemorrhage. Published results 
of head to head clinical trials or indirect comparisons efficacy inputs populated 
the model. Treatment algorithm was obtained from the local governmental guide. 
Public institutional direct medical costs (2014 purchases and price tabulators) where 
retrieved to adopt the national health system perspective. Governmental databases 
and 2014 purchases provided the epidemiology inputs. A five year forecast esti-
mated the budget impact of the use of tenecteplase versus streptokinase. Results: 
20,002 patients yearly were calculated to require medical attention due to an AMI in 
Mexico. Mean saving per patient in the tenecteplase versus the streptokinase arm 
was estimated to be US$1,920.00 at the CE model. 98% versus 93% positive response 
to treatment was seen at tenecteplase and streptokinase arms respectively. Starting 
at a 3% Market share level, and assuming an increasing share at a 3% rate per year, 
potential savings for new cases at year five (15% share) were estimated to be as high 
as US$16,371,461.00. ConClusions: At a better response rate with lower costs of 
treatment, tenecteplase was estimated to be a cost-saving therapy versus strepto-
kinase in a CE model. In a five year budget impact analysis, this novel alternative 
showed to bring potential savings in the public Mexican institutional context ver-
sus streptokinase. The savings proportionally increase with a higher market share.
PCV9
ImPACtO ORçAmEntáRIO DO EVEROLImO, SIROLImO E tACROLImO PARA 
ImUnOSSUPRESSãO Em tRAnSPLAntADOS CARDíACOS nO SIStEmA PúBLICO 
DE SAúDE DO BRASIL
Schneiders RE, Bastos EA, Domingues PH, Xavier LC, Reis FC, Alexandre RF,  
Nascimento Junior JM
Brazilian Ministry of Health, Brasília, Brazil
objetivos: Analisar o impacto orçamentário da do everolimo, sirolimo e tac-
rolimo para transplantados cardíacos no Sistema Público de Saúde do Brasil 
(SUS). Métodos: Para estimar a população que realizou transplante cardíaco no 
Brasil passível de utilizar esses medicamentos, desenhou-se coorte hipotética a 
partir do número de transplantes de coração no Brasil entre 1999 e 2013, obtido por 
meio do Sistema de Informações do SUS, e da taxa anual de sobrevida ao longo de 
15 anos, extraída de estudo de coorte multicêntrico internacional. Considerando 
que os medicamentos em análise estão disponíveis no SUS para transplantados 
Rankin Scale (mRs) was 3.8 , SD 0.8, 95 CI [3.4 - 4.1 ]. At day 15 follow-up NIHSS, 
was 11; SD 4.5; 95 CI [9.3 - 12.8 ]; mean mRs score was 1.9, SD 0.7, 95 CI [1.7 - 2.2 ], 
(p = 0.000 and 0.000 respectively).Only one patient report nightmares as adverse 
event. ConClusions: The current study demonstrate that cerebrolysin treatment 
improves functional outcome safely in Mexican patients with ASIS. Future double-
blind studies with larger sample sizes will further help to explore causal benefits 
of this drug in stroke outcome.
PCV4
A PhySICIAn-CEntERED IntERVEntIOn tO ImPROVE COntROL Of BLOOD 
PRESSURE: SyStEmAtIC REVIEw AnD mEtA-AnALySIS
Lima KM1, Ribeiro RA1, Ziegelmann P2, Leal L1, Schmidt F3, Polanczyk CA1
1Hospital Moinhos de Vento, Porto Alegre, Brazil, 2, Universidade Federal do Rio Grande do Sul, 
Porto Alegre, Brazil, 3Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
objeCtives: To review trials of physician-centered interventions to reducing sys-
tolic blood pressure (SBP) and diastolic blood pressure (DBP). Methods: Systematic 
review and meta-analysis. We searched MEDLINE, EMBASE and Cochrane Central for 
all-language articles up to September 2014. We included randomized controlled trial 
(RCT) of physician-centered interventions for hypertension compared with usual 
care or minimal intervention in primary care patients. Data were pooled using a 
random effect meta-analysis model. The effect were expressed as the weighted 
mean difference (WMD). Results: Twenty-five trials of 7595 citation were included. 
Seventeen studies were cluster RCT, one trial was factorial and cluster trial. The 
remaining seven studies were randomized at individual patient level; five of them 
used a two-by-two factorial design. Two studies did not report any estimates of vari-
ance. Overall, 23 trials (43.489 participants) was contribute to the meta-analysis. The 
physician-centered intervention were categorized as computer decision support (6 
trials), stepped treatment algorithm (6), Medical Education (4), Audit and feedback 
(3) and Multifaceted (4). Methodological quality of included studies was rather low. 
Only interventions that the main focus were stepped treatment algorithm showed 
significant reductions in blood pressure: weighted mean difference, systolic - 4.2 
mmHg; 95% confidence interval -5.3 to -3.2; I², 80.1% and diastolic -1.6 mmHg; 95% 
confidence interval -2.8 to -0.49; I². 93.4%. For the remaining five categories did not 
show to reducing blood pressure. Subgroup analyses by study design explained 
considerable heterogeneity in stepped treatment algorithm effect. ConClusions: 
Physician-centered interventions based in stepped treatment algorithm showed 
significantly reductions of systolic and diastolic blood pressure. The magnitude of 
reduction in blood pressure is likely to prevent stroke and death in patients.
PCV5
AntIPSyChOtIC ExPOSURE AnD RISk Of StROkE: A SyStEmAtIC REVIEw 
AnD mEtA-AnALySIS Of OBSERVAtIOnAL StUDIES
Hsu W1, Esmaily-Fard A2, Lee C3
1National Taiwan University Hospital, Taipei City, Taiwan, 2The University of Texas MD Anderson 
Cancer Center, Houston, TX, USA, 3National Taiwan University Hospital, Yunlin Branch, Douliou, 
Taiwan
bACkgRound: Use of antipsychotic medications has been associated with 
increased risk of cerebrovascular events; however, this association remains ques-
tionable given conflicting evidence in the literature. objeCtives: We conducted 
a systematic review and meta-analysis to determine the risk of stroke with the 
use of antipsychotic medications. Methods: All articles published between 
1970 and February 2015 were identified by comprehensively searching PubMed, 
MEDLINE and EMBASE without language restrictions. Observational studies com-
paring stroke outcomes in antipsychotic patients with non-users were selected. 
Two authors independently extracted study characteristics and indicators of study 
quality. Newcastle-Ottawa Scale was adopted to assess risk of bias. Pooled odd 
ratios (ORs) and heterogeneity (I2) were estimated on the basis of random effects 
models. Results: We identified 22 potentially relevant studies from 1,171 citations. 
Of these, 9 studies (3 cohort, 5 case–control and 1 case-case-time-control) with a 
total of 155,789 subjects and 10,203 cases of stroke were eligible for final analysis. 
Use of antipsychotics was associated with a significantly higher risk of developing 
stroke [OR 1.57, 95% confidence interval (CI) 1.29-1.98, I2 = 92.4%]. The pooled OR 
for stroke was 1.58 [95% CI 1.01-2.49, I2 = 68.4%] with exposure to conventional 
antipsychotics and 1.06 [95% CI 0.59-1.89, I2 = 56.2%] with exposure to atypical 
antipsychotics. Subgroup analysis of conventional antipsychotics showed elderly 
patients over 64 years old were at lower risk for stroke [OR 1.37, 95% CI 0.87-2.17, I2 
= 64.5%]. Due to limited data on individual agents, only Risperidone was evaluated 
in the subgroup analysis of atypical antipsychotics. Risperidone users were less 
likely to develop stroke than non-users of antipsychotics [OR 0.63, 95% CI 0.33-1.17, 
I2 = 55.2%]. ConClusions: Exposure to conventional antipsychotic was associated 
with a significant increase in stroke risk. Nonetheless, use of atypical antipsychotics 
revealed lower risk of stroke. Given heterogeneity among eligible studies, additional 
research is needed.
PCV6
BURDEn Of hEARt fAILURE In LAtIn AmERICA: A SyStEmAtIC REVIEw AnD 
mEtA-AnALySIS
Ciapponi A, Bardach A, Calderón M, Alcaraz A, Matta MG, Chaparro M, Soto N
Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina
objeCtives: Heart failure (HF) is a common clinical syndrome representing the 
end-stage of several cardiac diseases. Our objective was to estimate the burden of 
heart failure in Latin America. Methods: A systematic review and meta-analysis 
was performed. We searched in MEDLINE, EMBASE, LILACS, and CENTRAL from 
January 1994 to June 2014. We included non-comparative data from experimental 
and observational studies. No language restriction was imposed. We included stud-
ies with samples of at least 50 participants of 18 years of age or older with HF. The 
outcomes analyzed were incidence, prevalence, hospitalization rates and case fatal-
ity ratios of HF at different time points, length of stay and mortality. Results: The 
search retrieved 4792 references of which 143 studies were finally included. Most 
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Generalized linear regression models were used to examine associations between 
the total cost of hospitalization and various sociodemographic and clinical vari-
ables. Results: 301 patients were included; age 75.3 ± 11.8 years; 37% female; 57% 
with depressed ejection fraction; 46% of coronary artery disease. The blood pressure 
on admission was 129.8 ± 29.7 mmHg; renal function 26.2 ± 57.9 ml / min / 1.73 m2. 
In-hospital mortality was 7%. The length of stay was 7.82 ± 7.06 days (median 5.69), 
more prolonged in patients with renal impairment (8.59 vs. 8.18; p = 0.0329) and 
shorter in those with elevated blood pressure on admission (6.08 ± 4.03; p = 0.009). 
The average cost per patient was AR $ 68,861 ± 96,066 (US $ 8,071 ± 11,259; US $ 1 
= AR $ 8.7928); 71% attributable to hospital stay, 20% for therapeutic procedures 
(mainly aortic valve surgery, implanted defibrillator and coronary angioplasty) and 
6.7% for diagnostic studies (mainly radiology, laboratory and echocardiogram). In 
multivariate analysis, depressed ejection fraction, valve antecedent and impaired 
renal function at admission were associated with higher costs. ConClusions: 
Resource use and costs associated hospitalizations for heart failure are high, and 
the highest proportion is attributable to the costs of hospital stay.
PCV13
COStO – EfECtIVIDAD DE APIxABAn COn OtROS nOACS (DABIgAtRAn y 
RIVAROxABAn) En EL tRAtAmIEntO DE LA fIBRILACIOn AURICULAR nO 
VALVULAR (fAnV) En PACIEntES DE LA SEgURIDAD SOCIAL DE PERú
Sanabria C1, Cabrejos J1, Olortegui A2, Guevara C2, Garrido Lecca S3
1Universidad Nacional Mayor de San Marcos, Lima, Peru, 2Instituto Nacional Cardiovascular 
(INCOR), Lima, Peru, 3Bristol-Myers Squibb, Lima, Peru
objeCtivos: Análisis de costo-efectividad de apixaban versus otros NOACs (dabi-
gatrán y rivaroxaban) en pacientes con fibrilación auricular (FA) desde la perspectiva 
de la Seguridad Social peruana (EsSalud). MetodologíAs: Se adaptó un modelo 
de Markov con datos de eficacia y seguridad provenientes de los estudios clínicos 
pivotes de los NOACs – Aristoteles para apixaban. Para la estimación de frecuencia y 
costo de eventos se tomo como base los registros hospitalarios y tarifas oficiales de 
EsSalud también validándolos con expertos locales. Los costos de los medicamentos 
se obtuvieron del SEACE. Todos los costos se presentan a 2014 nuevos soles. La tasa 
de descuento utilizada fue de 3,5% para los costos y los resultados. Una cohorte de 
2.000 pacientes fue modelada para un horizonte temporal de toda la vida. Se real-
izó un análisis de sensibilidad probabilística y un análisis de sensibilidad univari-
ante. ResultAdos: Se estimaron el total de accidente cerebrovascular isquémico 
(no fatales moderado suave, no mortales, no mortales severa, fatal) apixaban: 147 vs 
dabigatrán-110mg: 154, dabigatrán-150mg: 146, rivaroxaban: 145. También se estimó el 
accidente cerebrovascular hemorrágico total (no fatales moderado suave, no mortales, 
no mortales severa, fatal) y otras grandes hemorragias (sangrado GI no fatales, ICH 
no fatal o no GI relacionados con hemorragias importantes, fatales). Los años de vida 
ajustados por calidad (AVAC), con apixaban se estimó 6,50 y un costo de S /. 27.473. 
Los otros NOACs tuvieron mayores costos y AVACs similares. Apixaban alcanzó cos-
tos incrementales negativos respecto de los otros NOACs, lo cual la hizo una opción 
dominante. En los resultados del análisis de sensibilidad univariable con diferentes 
entradas del modelo y en análisis de Monte Carlo, apixaban fue rentable en el 97% de 
las simulaciones utilizando el umbral de 1 PIB per cápita. ConClusiones: Apixaban 
es la alternativa más rentable en comparación con dabigatrán y rivaroxaban.
PCV14
COSt-EffECtIVEnESS Of APIxABAn VERSUS OthER nEw ORAL 
AntICOAgULAntS AnD wARfARIn fOR StROkE PREVEntIOn In AtRIAL 
fIBRILLAtIOn In VEnEzUELA
Fernández Ávila Y1, Garcia KC2, Garrido Lecca S3, Donato BM4, Juarez-Garcia A5
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bACkgRound: Apixaban (5 mg BID), dabigatran (150mg), and rivaroxaban (20 mg 
once daily) are 3 novel oral anticoagulants (NOACs) currently approved for stroke 
prevention in patients with atrial fibrillation (AF). Although warfarin remains the 
standard of care in Venezuela. objeCtives: The objective of this study was to evalu-
ate the cost-effectiveness of apixaban against other NOACs and warfarin from the 
perspective of the public health care sector in Venezuela. Methods: A Markov model 
was developed to evaluate the pharmacoeconomic impact of apixaban versus other 
NOACs over a lifetime. Direct comparisons from the Aristotle trial versus warfarin and 
pair-wise indirect treatment comparisons against other NOACs were used to assess 
relative effect size for following end points: ischemic stroke, hemorrhagic stroke, 
intracranial hemorrhage, other major bleeds, clinically relevant non major bleeds, 
myocardial infarction, and treatment discontinuations. Main outcomes are given in 
terms of costs per quality-adjusted life years gained. Resource use and costs were 
estimated from published data. Discount rate of 3.5% was used to discount both cost 
and QALYs. Results: Apixaban was projected to increase Qol versus other NOACs, 
and warfarin, QALY gained with apixaban when compared with dabigatran was .133, 
with rivaroxaban .132 and warfarin .32. Being the option with lower cost of all the 
comparators apixaban resulted in a dominant alternative. Sensitive analysis indi-
cated that warfarin option costs were very sensitive to INR monitoring frequency and 
cost but in general results were robust over a wide range of inputs. ConClusions: 
Although our analysis vs NOACs was limited by the absence of head-to-head trials, 
based on the indirect comparison data available, our model projects that apixaban 
may be a cost-effective alternative to dabigatran , rivaroxaban and warfarin for stroke 
prevention in AF patients from the perspective of the public health care in Venezuela.
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COStO-EfECtIVIDAD DE LOS nUEVOS AntICOAgULAntES ORALES En 
PACIEntES COn fIBRILACIOn AURICULAR nO VALVULAR En COLOmBIA
Garcia Peña AA
Pontificia Universidad Javeriana, Bogota, Colombia
objeCtivos: Realizar un análisis de costo-efectividad que compare las estrate-
gias de anticoagulación disponibles para el tratamiento de la fibrilación auricular 
renais e que essa condição possui um esquema terapêutico imunossupressor 
semelhante, utilizou-se a mesma frequência de uso desses medicamentos, em 2013. 
Considerou-se o preço de aquisição do Ministério da Saúde, por se tratar de uma 
análise sob a perspectiva dessa instituição. A taxa de câmbio considerada foi US$ 1 
= R$ 3,27. ResultAdos: No período analisado, 2.203 indivíduos realizaram trans-
plante de coração, dos quais 1.374 (62%) indivíduos estariam vivos. Dessa população, 
4,65% utilizariam everolimo, 7,34% sirolimo e 30,7% tacrolimo. O gasto anual por 
paciente varia conforme o medicamento e dose administrada: US$ 2.237,06 a US$ 
4.474,13 para everolimo; US$ 1.966,24 a US$ 4.915,60 para sirolimo; e US$ 1.193,39 a 
US$ 2.131,38 para tacrolimo. O impacto orçamentário anual para imunossupressão 
nesta população seria de US$ 844.715,35 a US$ 1.680.783,65, a depender da dose. 
Aproximadamente 57% do impacto deve-se ao gasto com tacrolimo. Caso toda a 
população que utilizasse everolimo migrasse para sirolimo, o impacto seria de US$ 
827.413,27 a US$ 1.708.987,45; no caso inverso, o impacto sofreria uma variação de 
US$ 872.021,56 a US$ 1.636.272,31 ConClusões: O estudo demonstra que a possível 
incorporação desses medicamentos não implicaria em significativo aporte orça-
mentário ao SUS, mas que deve ser ponderado frente às evidências que respaldem 
suas utilizações nessa população.
PCV10
EVALUAtIOn Of thE AnnUAL COSt Of fIxED-DOSE COmBInAtIOn 
DRUgS USED In tREAtmEnt Of hyPERtEnSIOn In InDIA: An ECOnOmIC 
PERSPECtIVE
Yadav D, Hussain S
National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India
objeCtives: To compute the cost of FDC drugs used in the treatment of hyperten-
sion and study the variation in the costs. Methods: Standard treatment guidelines 
(STG), 4th edition and Joint National committee (JNC), 8th guidelines were perused to 
understand the management of hypertension. Current Index of Medical Specialities 
(CIMS) Oct-Jan 2015 issue and Indian Drug Review (IDR) Issue 1, Jan 2015 were used to 
capture the prices of drugs available in the Indian market. Annual cost of treatment 
and its variation was studied. Results: First line FDC according to STG & JNC8 is 
calcium channel blockers/diuretics with beta-blockers or ACEI. If we initiated the 
treatment with amlodipine + atenolol (5mg + 50mg) OD, then the annual cost of 
treatment was found to be Rs.365-2909. A maximum variation of 697% was noted 
in the least-highest cost of treatment. A minimum of 144% variation was observed 
for amlodipine + lisinopril (5mg + 5mg) OD, in its least-highest cost of treatment. 
Likewise, if the treatment is initiated with other combination therapy, say ramipril + 
hydrochlorothiazide (2mg +12.5mg) OD, then annual cost of treatment was found to 
be Rs.365-2792. This showed a maximum variation of 665% in its least-highest cost 
of treatment. On the other hand hydrocholrothiazide + metoprolol (12.5 + 100mg) 
combination showed a minimum price variation of 9% only. ConClusions: It was 
concluded that a maximum of 8 fold variation was observed in the least-highest 
costs of treatment with amlodipine + atenolol (5mg + 50mg) in the year 2015. The 
average percentage price variation of different brands of the same oral antihyper-
tensive drug manufactured in India is very wide.
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COStO DE hIPERtEnSIOn ARtERIAL En LOS EStABLECImIEntOS DE SALUD 
DEL PERú
Escobedo-Palza S1, Timana-Ruiz R2, Sobrevilla-Ricci A3, Mosqueira-Lovón R3,  
Gutierrez-Aguado A4
1SPEAS, Lima, Peru, 2SOMPEGS, Lima, Peru, 3Abt Associates-HFG Peru, Lima, Peru, 4UNMSM, 
Lima, Peru
objeCtivos: Estimar los costos de Hipertensión Arterial (HTA) en los establecimien-
tos del Ministerio de Salud del Perú. MetodologíAs: Se realizó una evaluación 
económica parcial de tipo costo de enfermedad (CE). La población de estudio fue 
una cohorte hipotética de pacientes con HTA afiliada al Seguro Público de Salud 
(Seguro Integral de Salud) en el Perú. Los costos se estimaron desde la perspectiva 
del financiador tomados para el año 2014. La definición de los esquemas de manejo 
clínico (procedimientos médicos y medicamentos para el diagnóstico, tratamiento y 
seguimiento de la enfermedad) provienen de las Condiciones Asegurables del Plan 
Esencial de Aseguramiento en Salud (PEAS). Cada esquema de manejo clínico se 
ha estimado con la metodología de costeo estándar. El costo total fue ajustado por 
factores de oferta, demanda y adherencia. ResultAdos: La cohorte hipotética de 
HTA es de 359,672 personas para el año 2014 (Incidencia de HTA: 27%). El costo total 
para HTA es de 158,751,728 dólares. El costo total correspondiente a diagnóstico es 
5,098,754 dólares (3.2%), tratamiento 136,381,652 dólares (85.9%) y para seguimiento 
17,271,321 dólares (10.9%). El costo fijo correspondió a 55,294,137 dólares (34.8%) 
y el costo variable a 103,457,589 dólares (65.2%). ConClusiones: El costo anual 
total para Hipertensión Arterial en el Perú se estimó en 158,751,728 dólares. Este 
monto representa el 114.1% del presupuesto ejecutado el año 2014 en el Programa 
Presupuestal 018 Enfermedades no Transmisibles.
PCV12
RESOURCE USE AnD COStS Of COngEStIVE hEARt fAILURE 
hOSPItALIzAtIOnS: A REtROSPECtIVE COhORt StUDy In ARgEntInA
Augustovski F1, Caporale J1, Fosco M2, Alcaraz A1, Diez M3, Thierer J4, Peradejordi M2, 
Pichon Riviere A1
1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2Fundación 
Favaloro, Buenos Aires, Argentina, 3Instituto Cardiovascular de Buenos Aires (ICBA), Buenos Aires, 
Argentina, 4Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), 
Buenos Aires, Argentina
objeCtives: Describe the use of healthcare resources and costs of hospitalizations 
for congestive heart failure in three institutions of Argentina, in the entire popu-
lation subgroups such as ejection fraction, blood pressure and renal function at 
admission. Methods: Retrospective cohort study with descriptive and regression 
analysis. Means and medians were compared between subgroups using one-way 
ANOVA and Kruskal Wallis. The mortality rate was compared with chi square test. 
